作者
Christoph Schmid, Myriam Labopin, Arnon Nagler, Martin Bornhäuser, Jurgen Finke, Athanasios Fassas, Liisa Volin, Günham Gürman, Johan Maertens, Pierre Bordigoni, Ernst Holler, Gerhard Ehninger, Emmanuelle Polge, Norbert-Claude Gorin, Hans-Jochem Kolb, Vanderson Rocha
发表日期
2007/11/1
期刊
Journal of clinical oncology
卷号
25
期号
31
页码范围
4938-4945
出版商
American Society of Clinical Oncology
简介
Purpose
To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).
Patients and Methods
We retrospectively analyzed the data of 399 patients with AML in first hematological relapse after HSCT whose treatment did (n = 171) or did not (n = 228) include DLI. After correction for imbalances and established risk factors, the two groups were compared with respect to overall survival. Further, a detailed analysis of risk factors for survival among DLI recipients was performed.
Results
Median follow-up was 27 and 40 months, respectively. Estimated survival at 2 years (± standard deviation) was 21% ± 3% for patients receiving DLI and 9% ± 2% for patients not receiving DLI. After adjustment for differences between the groups, better outcome was associated with …
引用总数
学术搜索中的文章
C Schmid, M Labopin, A Nagler, M Bornhäuser… - Journal of clinical oncology, 2007